Preliminary analysis of the epidemiological effectiveness of COVID-19 vaccination in the Saratov Region

Abstract

The new coronavirus infection (COVID-19) caused by the SARS-CoV-2 virus continues to spread rapidly worldwide, despite the increased prevention and treatment measures being taken. Vaccination is one of the most cost-effective and effective methods of preventing infectious diseases in the modern world, including one of the most effective methods of combating COVID-19. Over several centuries of history, vaccination has proven its effectiveness in saving people’s lives, reducing the spread of infectious diseases among the population, as well as reducing mortality. The effectiveness of immunization against COVID-19 is an urgent problem at the moment, especially when it comes to vaccination.

The aim of the work is to study the effect of vaccination on the incidence of a new coronavirus infection among residents of the Saratov Region.

Material and methods. Methods of retrospective epidemiological analysis of trends in the epidemic process COVID-19 were used. The obtained materials were processed using methods of variational statistics (Excel program). The analysis was based on data from daily monitoring of laboratory diagnostic results (more than 1780 thousand PCR diagnostic studies were conducted during the epidemic), COVID-19 cases and deaths, taking into account the coverage of the population with preventive vaccinations. The statistical significance of the differences was assessed according to the Student’s criterion. The differences were considered significant at t≤2.

Results and discussion. As of June 30, 2021, more than 267 thousand people or 11% of the population of the Saratov region were fully vaccinated against COVID-19. There were no complications after the introduction of vaccines. In the structure of all medical immunobiological preparations that were immunized, the proportion of the vaccine “Gam-COVID-Vac” was 97.88%, “Epivaccorona” – 1.69% and “Covivac” – 0.43%. According to preliminary data, 361 of the vaccinated people were infected with SARS-CoV-2, of which: 255 (70.6%) had a mild course of the disease with manifestations of catarrhal syndrome, 84 (23.3%) had community-acquired pneumonia, 22 (6%) had no symptoms of the disease. No deaths have been registered among the vaccinated. The overall incidence of COVID-19 among vaccinated was 0.06%. The incidence rate of COVID-19 among the vaccinated population is 6.025±0.15 per 10 thousand people, which is significantly lower (t>2) than among the unvaccinated (103.8±0.63 per 10 thousand people), efficiency index – 17.23, epidemiological efficiency coefficient – 94.20%

Conclusion. Insufficient coverage of the population of the Saratov Region with vaccination (as of June 30, 2021, 11% were fully vaccinated) does not allow to influence the reduction of the incidence of COVID-19. The high epidemiological effectiveness of COVID-19 vaccination of the adult population with domestic vaccines, including people over 65 years of age, has been revealed.

Keywords:coronavirus (SARS-CoV-2); COVID-19 vaccine prophylaxis; new coronavirus infection; vaccination effectiveness

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

Contribution. Concept and design – Danilov A.N., Abramyan T.L., Mamonova I.A.; conducting the clinical part of the study- Danilov A.N., Abramyan T.L.; data analysis and processing – Abramyan T.L., Irishkova I.Е., Teisherskaya D.A.; writing the text of the article – Danilov A.N., Abramyan T.L., Mamonova I.A.

For citation: Danilov A.N., Abramyan T.L., Mamonova I.A., Irishkova I.E., Teisherskaya D.A. Preliminary analysis of the epidemiological effectiveness of COVID-19 vaccination in the Saratov Region. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2022; 11 (1): 34–40. DOI: https://doi.org/10.33029/2305-3496-2022-11-1-34-40

References

1. Asatryan M.N., Gerasimuk E.R., Lagunov D.Yu., Semenenko T.A., Ginzburg A.L. Forecasting the dynamics of the incidence of CAVID-19 and planning measures for vaccina­tion of the population of Moscow on the basis of mathematical modeling. Zhurnal mikrobiologii, èpidemiologii i immunobiologii [Journal of Microbiology, Epidemiology and Immunobiology]. 2020; 97 (4): 289–302. DOI: https://doi.org/10.36233/0372-9311-2020-97-4-1

2. Pollán M., Pérez-Gómez B., Pastor-Barriuso R., Oteo J., et al. Prevalence of SARSCoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020; 396 (10250): 535–44. DOI: http://doi.org/10.1016/S0140-6736(20)31483-5

3. The official Internet resource for informing the population about coronavirus (CO­VID-19). Stopcoronavirus.rf. 2021. https://стопкоронавирус.рф/about-covid/ (date of acess June 13, 2021). (in Russian)

4. Yushchuk N.D., Vengerov Yu.A., eds. Infectious diseases: national guidelines. Moscow: GEOTAR-Media; 2009: 1056. (Series “National guides”) (in Russian)

5. Briko N.I., Tsapkova N.N., Batyrshina L.R., Korshunov V.A., et al. Problems of vaccination prevention of the adult population. Èpidemiologiâ i vakcinoprofilaktika [Epidemiology and Vaccinal Prevention]. 2018; 17 (2): 4–15. DOI: https://doi.org/10.31631/2073-3046-2018-17-2-4-15 (in Russian)

6. Briko N.I., Mindlina A.Ya., Polibin R.V., Galina N.P., et al. Assessment of the attitude to immunoprophylaxis of various population groups of the Russian Federation. Zhurnal mikrobiologii [Journal of Microbiology]. 2017; (2): 98–103. DOI: https://doi.org/10.36233/0372-9311-2017-2-98-103 (in Russian)

7. Sheikh A., McMenamin J., Taylor B., Robertson C., et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021; 397 (10293): 2461–2. DOI: https://doi.org/10.1016/S0140-6736(21)01358-1

8. Danilov A.N., Eremin V.I., Abramyan T.L., Mamonova I.A., et al. Mortality from COVID-19 among people with HIV infection in the Saratov region. Žurnal infektologii [Journal of Infectology]. Appendix 1. 2021; 13 (3): 133. (in Russian)

9. Letter of the Ministry of Healthcare of the Russian Federation dated January 21, 2021 No. 1/4/1-333 “On the procedure for vaccination with the GAM-COVID-VAC vaccine against COVID-19 of the adult population”. (in Russian)

10. Order of the Ministry of Healthcare of the Russian Federation No. 47n dated 03.02.2021 “On Amendments to the calendar of preventive vaccinations for epidemic indications, approved by Order of the Ministry of Health of the Russian Federation No. 125n dated March 21, 2014”. (in Russian)

11. Decree of the Government of the Saratov Region dated June 16, 2021 No. 456-P “On Amendments to the Decree of the Government of the Saratov Region dated March 26, 2020 No. 208-P “On the introduction of restrictive measures in connection with the threat of the spread of coronavirus infection (COVID-19)”. (in Russian)

12. Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim anal­ysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397 (10275): 671–81. DOI: https://doi.org/10.1016/S0140-6736(21)00234-8

13. Petrov V.I., Gerasimenko A.S., Gorbatenko V.S., Shatalova O.V., Ponomareva A.V. Efficacy and safety of vaccines for the prevention of COVID-19. Lekarstvennyy vestnik [Medicinal Bulletin]. 2021; 15 (2): 3–7. (in Russian)

14. Ryzhikov A.B., Ryzhikov E.A., Bogryantseva M.P., et al. A simple blind placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the EpiVac­Corona vaccine for the prevention of COVID-19 on volunteers aged 18–60 years (phase I–II). Infektsiya i immunitet [Russian Journal of Infection and Immunity]. 2021; 11 (2): 283–96. (in Russian). DOI: https://doi.org/10.15789/2220-7619-ASB-1699

15. Temporary methodological recommendations “Procedure for vaccination of the adult population against COVID-19”; 2021. (in Russian)

16. Singanayagam A., Hakki S., Dunning J., Madon K.J., et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2022; 22 (2): 183–95. DOI: https://doi.org/10.1016/S1473-3099(21)00648-4

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»